Avandia, Actos Add Black Box; RECORD Leaves Heart Attack Risk Unresolved

FDA is adding a "black box" warning about the risk of congestive heart failure to thiazolidinediones while it continues to evaluate the potential risk of myocardial infarction seen in the class of type 2 diabetes therapies

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet